Amprius Technologies, Inc.
AMPXAmprius Technologies, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (7 weeks in). Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Amprius Technologies, Inc. trades at $10.8, building a base and 7 weeks into that stage. That is −21.5% against its own 200-day average. It sits at 27% of a 52-week range of $7 to $21. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (9 weeks and counting).
Today the stock is building a base — week 7 of stage 1. At $10.8 it trades −21.5% versus its 200-day average and sits at 27% of its 52-week range ($7–$21).
Against the market, two honest reads. Cumulative: over the last 3.9 years the stock moved +30% while the S&P 500 moved +100% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-06-05) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price Amprius Technologies, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Amprius Technologies, Inc. at 28.6× its FY25 revenue of $0.1 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Amprius Technologies, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +250.0% | — | — | — |
| Stock price | +70.0% | +15.6% | — | — |
4-Factor Sector Score
42.8/100 — rank 18 of 30 in Electrical Equipment & Parts · 61% evidence confidence
Amprius Technologies, Inc. scores 42.8 out of 100 against the 30 companies it is compared with in Electrical Equipment & Parts, ranking 18. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.1% and the one-year return is 34.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
The four contributions add to the total exactly: 24.6 + 5.9 + 10 + 2.3 = 42.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Amprius Technologies, Inc. reported $0.0 B of revenue in the Mar 26 quarter, +200.0% year on year. That is the 3rd straight quarter of year-on-year growth. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.1 B.
FY25 revenue came in at $0.1 B (+250.0% on the year). The latest quarter (Mar 26) printed $0.0 B, +200.0% year on year — the 3rd consecutive quarter of year-over-year growth.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Amprius Technologies, Inc.'s operating margin is −33.3% in the Mar 26 quarter, +66.7 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −400.0% to −71.4%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is −33.3%, +66.7 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −400.0%–−71.4%.
Why the margin moved: operating margin went +66.7 pp year on year while gross margin went +33.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Amprius Technologies, Inc. posted a net loss of $0.01 B in the Mar 26 quarter. The full FY25 year was a loss of $0.04 B. That loss is 33.3% of the quarter's revenue. The same quarter a year earlier lost $0.01 B. 11 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.0 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Amprius Technologies, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $−0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.0 B against reported profit of $−0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Amprius Technologies, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Amprius Technologies, Inc. earns a ROE of −40% in FY25. That is up from a trough of −100% in FY21. Return on invested capital clears the cost of that capital by −26.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −57.1% net margin on 0.44× asset turns.
FY25 ROE is −40%, recovered from a FY21 trough of −100% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): −57.1% net margin × 0.44× asset turns × 1.60× balance-sheet leverage ≈ −40.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: −9.4% − 17.1% = a −26.5 pp spread. The 17.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Amprius Technologies, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Amprius Technologies, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Amprius Technologies, Inc. carries total debt of $0.0 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 0.09 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.40 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $0.1 B — a debt-to-equity of 0.09. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.40 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
19.9% of Amprius Technologies, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 3.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 19.9% of the float is sold short, and at typical trading volumes it would take about 3.8 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Amprius Technologies, Inc.: the Z-score reads 30.29. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 30.29 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 30.29.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Advanced Energy Industries, Inc.AEIS | 66.9/100Favorable setup81% evidence | ASLEEP | 26.6/35 Revenue 22.2% · PAT 100% · OPM change 5.8 pp 83% evidence | 13.6/25 ROCE 3.8% · OPM 13.4% 76% evidence | 11.8/20 P/E 67.9× · PEG 0.94 65% evidence | 14.9/20 RS sector 13% · RS bench 16.3% · 1Y 126.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 13.6 + 11.8 + 14.9 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Espey Mfg. & Electronics Corp.ESP | 63.3/100Mixed-positive evidence75% evidence | ASLEEP | 19.3/35 Revenue -8.7% · PAT 37.5% · OPM change 9.1 pp 83% evidence | 16.1/25 ROCE 5.8% · OPM 26.1% 76% evidence | 16.0/20 P/E 14.5× · PEG 0.34 65% evidence | 11.9/20 RS sector 0.4% · RS bench 5% · 1Y 42.1%0 of 12 weeks ahead 70% evidence |
| Exact sum: 19.3 + 16.1 + 16 + 11.9 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Preformed Line Products CompanyPLPC | 61.3/100Thin evidence · provisional58% evidence | TURNING | 18.2/35 Revenue — · PAT — · OPM change -1 pp 45% evidence | 14.4/25 ROCE 5.2% · OPM 7.8% 76% evidence | 9.8/20 P/E 46.2× · PEG — 15% evidence | 18.9/20 RS sector 37% · RS bench 41.6% · 1Y 166.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 14.4 + 9.8 + 18.9 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4nVent Electric plcNVT | 59.6/100Thin evidence · provisional58% evidence | FADING | 18.9/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 15.0/25 ROCE 5.1% · OPM 15.8% 76% evidence | 9.6/20 P/E 46.3× · PEG — 15% evidence | 16.1/20 RS sector 14.8% · RS bench 19.1% · 1Y 82.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 15 + 9.6 + 16.1 = 59.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Acuity Inc.AYI | 58.5/100Mixed-positive evidence85% evidence | BREAKING OUT | 20.4/35 Revenue 10.5% · PAT 17.7% · OPM change 4.2 pp 95% evidence | 15.4/25 ROCE 5% · OPM 16.1% 76% evidence | 12.1/20 P/E 20.2× · PEG 1.07 65% evidence | 10.6/20 RS sector -9.5% · RS bench -3.6% · 1Y 13.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 15.4 + 12.1 + 10.6 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Atkore Inc.ATKR | 58.1/100Mixed-positive evidence64% evidence | TURNING | 19.6/35 Revenue -3.4% · PAT -162.5% · OPM change 8.8 pp 62% evidence | 9.7/25 ROCE 0.5% · OPM 1.4% 76% evidence | 10.2/20 P/E 22.8× · PEG — 15% evidence | 18.6/20 RS sector 17.7% · RS bench 23.5% · 1Y 70.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 9.7 + 10.2 + 18.6 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Vertiv Holdings CoVRT | 57.4/100Thin evidence · provisional58% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 2.3 pp 45% evidence | 16.4/25 ROCE 8.3% · OPM 16.6% 76% evidence | 9.1/20 P/E 75.8× · PEG — 15% evidence | 12.8/20 RS sector 5.1% · RS bench 7.8% · 1Y 92.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 16.4 + 9.1 + 12.8 = 57.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Bloom Energy CorporationBE | 56.7/100Thin evidence · provisional58% evidence | FADING | 22.4/35 Revenue — · PAT — · OPM change 15.4 pp 45% evidence | 12.3/25 ROCE 5.5% · OPM 9.6% 76% evidence | 8.5/20 P/E 403.6× · PEG — 15% evidence | 13.5/20 RS sector 31.4% · RS bench 31.8% · 1Y 519.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 12.3 + 8.5 + 13.5 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Hayward Holdings, Inc.HAYW | 51.9/100Thin evidence · provisional58% evidence | TURNING | 18.0/35 Revenue — · PAT — · OPM change 2 pp 45% evidence | 14.1/25 ROCE 2.7% · OPM 16.6% 76% evidence | 10.7/20 P/E 22.3× · PEG — 15% evidence | 9.1/20 RS sector -12% · RS bench -6.4% · 1Y 6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 14.1 + 10.7 + 9.1 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10EnerSysENS | 51.4/100Mixed-positive evidence81% evidence | ASLEEP | 10.5/35 Revenue 3.7% · PAT -19.8% · OPM change -1 pp 83% evidence | 14.2/25 ROCE 3.9% · OPM 12.5% 76% evidence | 14.6/20 P/E 22.6× · PEG 0.49 65% evidence | 12.1/20 RS sector 2.6% · RS bench 5.6% · 1Y 102.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 14.2 + 14.6 + 12.1 = 51.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11Hubbell IncorporatedHUBB | 51.2/100Thin evidence · provisional58% evidence | ASLEEP | 15.7/35 Revenue — · PAT — · OPM change 0.5 pp 45% evidence | 15.6/25 ROCE 4.6% · OPM 17.4% 76% evidence | 10.1/20 P/E 31× · PEG — 15% evidence | 9.8/20 RS sector -9.3% · RS bench -4.4% · 1Y 20%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 15.6 + 10.1 + 9.8 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Electrovaya Inc.ELVA | 50.9/100Mixed-positive evidence75% evidence | ASLEEP | 20.6/35 Revenue 50% · PAT 100% · OPM change 2.8 pp 83% evidence | 11.1/25 ROCE 3.3% · OPM 12.1% 76% evidence | 6.5/20 P/E 71.1× · PEG 2.27 65% evidence | 12.7/20 RS sector 1.8% · RS bench 5.2% · 1Y 98.9%7 of 12 weeks ahead 70% evidence |
| Exact sum: 20.6 + 11.1 + 6.5 + 12.7 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Energizer Holdings, Inc.ENR | 48.1/100Mixed-negative evidence65% evidence | TURNING | 18.8/35 Revenue 2.7% · PAT 100% · OPM change 1.5 pp 83% evidence | 12.0/25 ROCE 2.4% · OPM 13.5% 76% evidence | 11.3/20 P/E 6× · PEG — 15% evidence | 6.0/20 RS sector -17% · RS bench -10.6% · 1Y -25%5 of 12 weeks ahead 70% evidence |
| Exact sum: 18.8 + 12 + 11.3 + 6 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Kimball Electronics, Inc.KE | 47.3/100Mixed-negative evidence75% evidence | ASLEEP | 15.5/35 Revenue -6.3% · PAT 50% · OPM change 0.2 pp 83% evidence | 11.0/25 ROCE 1.6% · OPM 3.3% 76% evidence | 14.4/20 P/E 22.8× · PEG 0.49 65% evidence | 6.4/20 RS sector -15.5% · RS bench -9.9% · 1Y 36.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 15.5 + 11 + 14.4 + 6.4 = 47.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15FuelCell Energy, Inc.FCEL | 46.2/100Mixed-negative evidence64% evidence | LEADER | 11.5/35 Revenue 31% · PAT — · OPM change -123.2 pp 71% evidence | 4.7/25 ROCE -8.9% · OPM -218.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 81.3% · RS bench 83.2% · 1Y 426.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 4.7 + 10 + 20 = 46.2 · Decision use: Price leads the evidence: RS versus the benchmark is 83.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Eos Energy Enterprises, Inc.EOSE | 43.6/100Mixed-negative evidence64% evidence | ASLEEP | 26.1/35 Revenue 100% · PAT — · OPM change 367 pp 62% evidence | 4.7/25 ROCE -18.7% · OPM -139.2% 76% evidence | 11.2/20 P/E 6.3× · PEG — 15% evidence | 1.6/20 RS sector -61.8% · RS bench -59.5% · 1Y -31.7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 26.1 + 4.7 + 11.2 + 1.6 = 43.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -61.8% and the one-year return is -31.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 17Powell Industries, Inc.POWL | 43.0/100Mixed-negative evidence81% evidence | ASLEEP | 9.3/35 Revenue 4.5% · PAT 7.5% · OPM change -1.7 pp 83% evidence | 17.0/25 ROCE 8.9% · OPM 19.4% 76% evidence | 4.9/20 P/E 35.3× · PEG 4.52 65% evidence | 11.8/20 RS sector 9.2% · RS bench 10.8% · 1Y 160.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 9.3 + 17 + 4.9 + 11.8 = 43 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 18Amprius Technologies, Inc.this pageAMPX | 42.8/100Mixed-negative evidence61% evidence | ASLEEP | 24.6/35 Revenue 100% · PAT — · OPM change 62.3 pp 62% evidence | 5.9/25 ROCE -6.1% · OPM -23.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.3/20 RS sector -26.1% · RS bench -23.8% · 1Y 34.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 5.9 + 10 + 2.3 = 42.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.1% and the one-year return is 34.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 19T1 Energy Inc.TE | 41.7/100Thin evidence · provisional53% evidence | FADING | 19.0/35 Revenue — · PAT — · OPM change 35.2 pp 39% evidence | 7.8/25 ROCE -2.5% · OPM -12.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.9/20 RS sector -11.9% · RS bench -11% · 1Y 324.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 7.8 + 10 + 4.9 = 41.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Plug Power Inc.PLUG | 39.0/100Mixed-negative evidence61% evidence | ASLEEP | 19.9/35 Revenue 15.3% · PAT — · OPM change 66.5 pp 62% evidence | 6.1/25 ROCE -4.7% · OPM -67% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -23.6% · RS bench -20.7% · 1Y 43%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 6.1 + 10 + 3 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21SKYX Platforms Corp.SKYX | 35.0/100Thin evidence · provisional55% evidence | ASLEEP | 15.8/35 Revenue 8.1% · PAT — · OPM change 1.4 pp 62% evidence | 4.7/25 ROCE -17.9% · OPM -36.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.5/20 RS sector -37.7% · RS bench -34% · 1Y -1.7%1 of 12 weeks ahead 70% evidence |
| Exact sum: 15.8 + 4.7 + 10 + 4.5 = 35 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22GrafTech International Ltd.EAF | 30.6/100Thin evidence · provisional58% evidence | BASING | 10.2/35 Revenue 0.6% · PAT — · OPM change -8.2 pp 62% evidence | 7.3/25 ROCE -3.2% · OPM -24.5% 76% evidence | 9.0/20 P/E 76.6× · PEG — 15% evidence | 4.1/20 RS sector -41% · RS bench -36.8% · 1Y -39.5%5 of 12 weeks ahead 70% evidence |
| Exact sum: 10.2 + 7.3 + 9 + 4.1 = 30.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Arxis, Inc.ARXS | 47.7/100Thin evidence · provisional27% evidence | TURNING | 17.3/35 Revenue — · PAT — · OPM change 3.6 pp 13% evidence | 11.6/25 ROCE 1% · OPM 24.2% 76% evidence | 8.8/20 P/E 150.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 17.3 + 11.6 + 8.8 + 10 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Forgent Power Solutions, Inc.FPS | 46.0/100Thin evidence · provisional38% evidence | ASLEEP | 16.0/35 Revenue — · PAT — · OPM change -1.6 pp 45% evidence | 11.3/25 ROCE 2.9% · OPM 10.4% 76% evidence | 8.7/20 P/E 250.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 16 + 11.3 + 8.7 + 10 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Ballard Power Systems Inc.BLDP | 42.2/100Thin evidence · provisional49% evidence | ASLEEP | 20.2/35 Revenue — · PAT — · OPM change 118.5 pp 45% evidence | 6.5/25 ROCE -2.7% · OPM -70.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.5/20 RS sector -20.5% · RS bench -17.8% · 1Y 52.2%7 of 12 weeks ahead 70% evidence |
| Exact sum: 20.2 + 6.5 + 10 + 5.5 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26X-Energy, Inc.XE | 42.0/100Thin evidence · provisional28% evidence | ASLEEP | 17.5/35 Revenue — · PAT — · OPM change -25.8 pp 26% evidence | 4.5/25 ROCE -11.9% · OPM -152.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 2 weeks ahead 0% evidence |
| Exact sum: 17.5 + 4.5 + 10 + 10 = 42 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27ADS-TEC Energy PLCADSE | 41.6/100Thin evidence · provisional32% evidence | TURNING | 16.0/35 Revenue — · PAT — · OPM change — 9% evidence | 7.3/25 ROCE -30.3% · OPM — 46% evidence | 11.5/20 P/E 0.1× · PEG — 15% evidence | 6.8/20 RS sector -13% · RS bench -7.8% · 1Y 2.3%1 of 12 weeks ahead 70% evidence |
| Exact sum: 16 + 7.3 + 11.5 + 6.8 = 41.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Factorial Energy Inc.FAC | 41.3/100Thin evidence · provisional18% evidence | ASLEEP | 16.1/35 Revenue — · PAT — · OPM change — 8% evidence | 5.2/25 ROCE -34.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y -41.2%4 of 12 weeks ahead 0% evidence |
| Exact sum: 16.1 + 5.2 + 10 + 10 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Lightbridge CorporationLTBR | 41.2/100Thin evidence · provisional41% evidence | ASLEEP | 20.2/35 Revenue — · PAT — · OPM change — 33% evidence | 7.3/25 ROCE -5.6% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -47.7% · RS bench -43.7% · 1Y -35.1%0 of 12 weeks ahead 70% evidence |
| Exact sum: 20.2 + 7.3 + 10 + 3.7 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Enovix CorporationENVX | 39.8/100Thin evidence · provisional49% evidence | ASLEEP | 21.1/35 Revenue — · PAT — · OPM change 8 pp 45% evidence | 5.3/25 ROCE -7.2% · OPM -577.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.4/20 RS sector -51.4% · RS bench -47.5% · 1Y -59.2%4 of 12 weeks ahead 70% evidence |
| Exact sum: 21.1 + 5.3 + 10 + 3.4 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Amprius Technologies, Inc.'s stock price today?
Amprius Technologies, Inc. trades at $10.8, +70.0% over the past year. The company is valued at $2.0 B. The stock sits at 27% of its 52-week range of $7–$21, −21.5% versus its 200-day average. On the tape, the price is building a base, 7 weeks in. — as of 5 August 2026.
What were Amprius Technologies, Inc.'s latest quarterly results?
Amprius Technologies, Inc. reported revenue of $0.0 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.04. The operating margin was −33.3%, 66.7 pp higher than a year earlier. — as of 5 August 2026.
What is Amprius Technologies, Inc.'s revenue?
Amprius Technologies, Inc. reported revenue of $0.0 B in the Mar 26 quarter, +200.0% year on year. For the full FY25 fiscal year, revenue was $0.1 B (+250.0%). — as of 5 August 2026.
What is Amprius Technologies, Inc.'s profit?
Amprius Technologies, Inc. earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.0 B. The operating margin ran −33.3% in the latest quarter. — as of 5 August 2026.
What is Amprius Technologies, Inc.'s market cap?
Amprius Technologies, Inc.'s market capitalisation is $2.0 B at a stock price of $10.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Amprius Technologies, Inc. pay a dividend?
No — Amprius Technologies, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is Amprius Technologies, Inc. performing?
Amprius Technologies, Inc. is building a base, 7 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Amprius Technologies, Inc. in an uptrend?
No — the price is building a base (week 7 of stage 1), trading −21.5% versus its 200-day average and at 27% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Amprius Technologies, Inc. beating the market?
Not lately — on a trailing-13-week view Amprius Technologies, Inc. is currently behind the S&P 500 (9 weeks and counting; last ahead the week of 2026-06-05), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.9 years the stock moved +30% against the S&P 500's +100% — behind the index over the full window. — as of 5 August 2026.
Will Amprius Technologies, Inc.'s stock price go up?
This page publishes no price forecast for Amprius Technologies, Inc. What it measures instead: the stock price is $10.8, the price is building a base 7 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Amprius Technologies, Inc.?
Yes — short interest is 19.9% of Amprius Technologies, Inc.'s tradable float, about 3.8 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Amprius Technologies, Inc. have too much debt?
No — Amprius Technologies, Inc.'s debt-to-equity is 0.05. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is Amprius Technologies, Inc.'s capex?
Amprius Technologies, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Amprius Technologies, Inc.'s cash flow?
Amprius Technologies, Inc. generated $−0.0 B of operating cash flow in FY25 and $−0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is Amprius Technologies, Inc.?
On the balance sheet, the Z-score reads 30.29 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Amprius Technologies, Inc. in its business cycle?
Amprius Technologies, Inc.'s FY25 operating margin was −71.4%, against a 3-year band of −400.0%–−71.4%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −33.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Amprius Technologies, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Amprius Technologies, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Amprius Technologies, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.